Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Total Liabilities (2016 - 2025)

STRATA Skin Sciences (SSKN) has disclosed Total Liabilities for 14 consecutive years, with $27.6 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 7.82% to $27.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.6 million through Dec 2025, down 7.82% year-over-year, with the annual reading at $27.6 million for FY2025, 7.82% down from the prior year.
  • Total Liabilities hit $27.6 million in Q4 2025 for STRATA Skin Sciences, down from $29.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $38.3 million in Q2 2023 to a low of $19.1 million in Q2 2021.
  • Historically, Total Liabilities has averaged $28.5 million across 5 years, with a median of $29.8 million in 2023.
  • Biggest five-year swings in Total Liabilities: skyrocketed 63.6% in 2022 and later decreased 23.61% in 2024.
  • Year by year, Total Liabilities stood at $21.2 million in 2021, then soared by 43.73% to $30.4 million in 2022, then fell by 3.66% to $29.3 million in 2023, then grew by 2.14% to $30.0 million in 2024, then fell by 7.82% to $27.6 million in 2025.
  • Business Quant data shows Total Liabilities for SSKN at $27.6 million in Q4 2025, $29.4 million in Q3 2025, and $29.0 million in Q2 2025.